Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547890 | 0.87 | ESR1 (0.40) | ESR1ESR2PRMT5WDR77NPC1 | |
| SCHEMBL22768844 | 0.80 | ESR1 (0.41) | ESR1ESR2CYP2C9PRMT5WDR77 | |
| SCHEMBL5102670 | 0.77 | ESR1 (0.44) | ESR1ESR2PRMT5WDR77NPC1 | |
| SCHEMBL21385482 | 0.76 | CYP19A1 (0.33) | ESR1ESR2 | |
| SCHEMBL2077948 | 0.76 | ESR1 (0.47) | ESR1ESR2LMNA | |
| SCHEMBL19782445 | 0.76 | KDM4E (0.38) | RAB9A | |
| SCHEMBL6919625 | 0.76 | CCR1 (0.41) | RAB9AMAPT | |
| SCHEMBL30189703 | 0.76 | KDM4E (0.38) | RAB9A | |
| SCHEMBL19107508 | 0.75 | ESR1 (0.37) | ESR1ESR2PRMT5WDR77NPC1 | |
| SCHEMBL2604908 | 0.75 | ESR1 (0.42) | ESR1ESR2CYP2D6PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | ESR1 1851/4885ESR2 1331/4885CYP2D6 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.